Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
The deal, which will see Lilly hand over an undisclosed upfront payment and funding for Profluent's R&D efforts, could deem the biotech eligible for $2.25bn in development and commercial milestones. Profluent will also see tiered royalties on net sales if any of the developed recombinases were to make it to market. Through this partnership, Lilly and Profluent will work across multiple programmes, which will focus on developing and commercialising site-specific recombinases for diseases with “severe unmet needs”. To achieve this, Profluent will take an AI-driven approach – using the technology to create and optimise custom recombinases targeting exact locations in the genome to enable large-scale, precise DNA editing. Under the deal's terms, Lilly will also gain the exclusive rights to take selected recombinases through both early and clinical development to commercialisation. According to Profluent, altering DNA on a kilobase scale could help address the variation in mutations
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- FDA tests out ‘real-time' clinical trials; AbbVie closes in on a KRAS biotech [Yahoo! Finance]Yahoo! Finance
- FDA Decisions Put Johnson & Johnson's Growth And Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- ‘American industry is winning': White House touts factory boom — how investors can ride the reshoring wave [Yahoo! Finance]Yahoo! Finance
- Poolbeg eyes transformative summer with POLB 001 data in prospect [Yahoo! Finance]Yahoo! Finance
- CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/28/26 - Form 8-K
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- JNJ's page on the SEC website